Advancing our understanding of neuroplasticity and the development of novel therapeutics based upon this knowledge is critical in order to improve the treatment and prevention of a myriad of nervous system disorders. Epigenetic mechanisms of neuroplasticity involve the post-translational modification of chromatin and the recruitment or loss of macromolecular complexes that control neuronal activitydependent gene expression. While over a century after Ramón y Cajal first described nuclear subcompartments and foci that we now know correspond to sites of active transcription with acetylated histones that are under epigenetic control, the rate and extent to which epigenetic processes act in a dynamic and combinatorial fashion to shape experience-dependent phenotypic and behavioral plasticity in response to various types of neuronal stimuli over a range of time scales is only now coming into focus. With growing recognition that a subset of human diseases involving cognitive dysfunction can be classified as 'chromatinopathies', in which aberrant chromatin-mediated neuroplasticity plays a causal role in the underlying disease pathophysiology, understanding the molecular nature of epigenetic mechanisms in the nervous system may provide important new avenues for the development of novel therapeutics. In this review, we discuss the chemistry and neurobiology of the histone deacetylase (HDAC) family of chromatinmodifying enzymes, outline the role of HDACs in the epigenetic control of neuronal function, and discuss the potential relevance of these epigenetic mechanisms to the development of therapeutics aiming to enhance memory and neuroplasticity. Finally, open questions, challenges, and critical needs for the field of 'neuroepigenetics' in the years to come will be summarized.
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1. Introduction
Chromatin as a substrate for epigenetic control
Recent molecular, cellular, and behavioral findings have revealed the importance of epigenetic mechanisms that alter chromatin structure in maintaining stable patterns of gene expression and altering neuroplasticity associated with memory formation (reviewed in Barrett and Wood (2008) and Levenson and Sweatt (2005) ), mood (Berton & Nestler, 2006; Tsankova, Renthal, Kumar, & Nestler, 2007) , drug addiction (reviewed in Renthal and Nestler (2008) ), neuroprotection (Kazantsev & Thompson, 2008) , and other forms of experience-dependent input into the nervous system. Collectively, these findings have provided new insight into the cellular and molecular mechanisms through which gene expression affects neurotransmission and behavioral plasticity over long time periods. This in turn has led to a growing desire to understand the nature of epigenetic regulation in the nervous system in greater detail.
At the heart of epigenetic regulatory mechanisms is the fundamental unit of chromatin in all eukaryotic cells, the nucleosome, composed of 147 base pairs of DNA wrapped around two copies of specific variants of each of the core histones H2A, H2B, H3, and H4, along with one copy of the liker histone H1. By packaging DNA and controlling the access of other factors, epigenetic mechanisms provide an important level of control of gene expression throughout development and in post-mitotic cells, such as neurons.
With its repeating nucleosomal units, chromatin as a polymer is well designed to be a 'plastic' substrate that can respond to both fast and short-term changes in neuronal signaling and cell states within the nervous system. To alter gene expression states in neurons, as in all other cell types, epigenetic regulatory processes involves the dynamic interplay of two major classes of multiprotein, macromolecular complexes: (1) ATP-dependent remodeling complexes, which alter the position of nucleosomes to either increase or decrease transcription (reviewed in Racki and Narlikar (2008)); and (2) histone-modifying complexes, which post-translationally modify the N-terminal tails of histone proteins through acetylation, methylation, phosphorylation, ubiquitinylation, sumoylation, glycosylation, and ribosylation (Borrelli, Nestler, 
